Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
We conduct this study to investigate the efficacy of triple therapy (high-dose
glucocorticoids + cyclophosphamide + calcineurin inhibitor) compared with dual-therapy
regimens (high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor) and whether it
reduces the risk of poor pulmonary prognosis in patients with moderate to high risk
anti-MDA5+ DM.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University